People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $150.9M | $3.3B | 2016 |
| Solstice Biologics LLC | — | Pharmaceuticals | Series A | $22.0M | $123.9M | 2014 |
| Ember Therapeutics, Inc. | — | Biotechnology | Seed | $3.2M | $141.7M | 2011 |
Louis Tartaglia at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Louis Tartaglia on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Corey Goodman | 1 | 13 |
| Todd Foley | 1 | 12 |
| Kush Parmar | 1 | 10 |
| Mitchell Bloom | 1 | 6 |
| Robert Adelman | 1 | 5 |
| Frank Muhlenbeck | 1 | 4 |
| Christine Brennan | 1 | 3 |
| Kevin Gillis | 1 | 3 |
| John Borgeson | 1 | 3 |
| KUSH M. PARMAR | 1 | 3 |
| Anja Harmeier | 1 | 2 |
| Mario Saltarelli | 1 | 2 |
| John F. Crowley | 1 | 2 |
| John Crowley | 1 | 2 |
| Steven Dowdy | 1 | 1 |
| Carole F. Nuechterlein | 1 | 1 |
| Natarajan F. Sethuraman | 1 | 1 |
| Todd F. Foley | 1 | 1 |
| Peter F. Kim | 1 | 1 |
| Curt Bradshaw | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.